Localized adenocarcinoma of the esophagogastric junction - Is there a standard of care?

Cancer Treatment Reviews

Volumn 36, Issue 5, 2010, Pages 400-409

  Power, D G ^a   Reynolds, J V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Adenocarcinoma; Chemotherapy; Esophagogastric junction; Radiation; Surgery; Targeted therapy

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL; SORAFENIB; SUNITINIB; THYMIDYLATE SYNTHASE;

ABDOMEN; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENE AMPLIFICATION; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE; LYMPHADENECTOMY; MICROSCOPY; NECK; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; THORAX; THORAX RADIOGRAPHY; TREATMENT RESPONSE; ADENOCARCINOMA; CANCER STAGING; ESOPHAGEAL NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77955092661     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.01.001     Document Type: Review

References (119)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Blot W.J., Devesa S.S., Kneller R.W., Fraumeni J.F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. Jama 1991, 265:1287-1289.
3. Catalano V., Labianca R., Beretta G.D., Gatta G., de Braud F., Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2009, 19:19.
4. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
5. Bird-Lieberman E.L., Fitzgerald R.C. Early diagnosis of oesophageal cancer. Br J Cancer 2009, 101:1-6.
6. Kamangar F., Dawsey S.M., Blaser M.J., et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006, 98:1445-1452.
7. Ryan A.M., Healy L.A., Power D.G., et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008, 247:909-915.
8. Ye W., Held M., Lagergren J., et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004, 96:388-396.
9. Siewert J.R., Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998, 85:1457-1459.
10. Chandrasoma P., Wickramasinghe K., Ma Y., De Meester T. Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas. Am J Surg Pathol 2007, 31:569-575.
11. El-Rifai W., Frierson H.F., Moskaluk C.A., et al. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001, 121:592-598.
12. Gomes L.I., Esteves G.H., Carvalho A.F., et al. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism. Cancer Res 2005, 65:7127-7136.
13. Wijnhoven B.P., Siersema P.D., Hop W.C., van Dekken H., Tilanus H.W. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam oesophageal tumour study group. Br J Surg 1999, 86:529-535.
14. Hulscher J.B., van Sandick J.W., de Boer A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002, 347:1662-1669.
15. Omloo J.M., Lagarde S.M., Hulscher J.B., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007, 246:992-1000. [discussion - 1].
16. Hagen J.A., DeMeester S.R., Peters J.H., Chandrasoma P., DeMeester T.R. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001, 234:520-530. [discussion 30-1].
17. Rizzetto C., DeMeester S.R., Hagen J.A., Peyre C.G., Lipham J.C., DeMeester T.R. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2008, 135:1228-1236.
18. Peyre C.G., Hagen J.A., DeMeester S.R., et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008, 248:979-985.
19. Peyre C.G., Hagen J.A., DeMeester S.R., et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008, 248:549-556.
20. Wayman J., Bennett M.K., Raimes S.A., Griffin S.M. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002, 86:1223-1229.
21. Kamangar F., Chow W.H., Abnet C.C., Dawsey S.M. Environmental causes of esophageal cancer. Gastroenterol Clin North Am 2009, 38:27-57. [vii].
22. Greenawalt D.M., Duong C., Smyth G.K., et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer 2007, 120:1914-1921.
23. Mathe E.A., Nguyen G.H., Bowman E.D., et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009, 15:6192-6200.
24. Chau I., Norman A.R., Cunningham D., et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma-individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 2009, 20:885-891.
25. Hulscher J.B., van Lanschot J.J. Individualised surgical treatment of patients with an adenocarcinoma of the distal oesophagus or gastro-oesophageal junction. Dig Surg 2005, 22:130-134.
26. Whitson B.A., Groth S.S., Li Z., Kratzke R.A., Maddaus M.A. Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. J Thorac Cardiovasc Surg 2009, 12:12.
27. Allum W.H., Stenning S.P., Bancewicz J., Clark P.I., Langley R.E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 21:21.
28. Gebski V., Burmeister B., Smithers B.M., Foo K., Zalcberg J., Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007, 8:226-234.
29. Reynolds J.V., Muldoon C., Hollywood D., et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007, 245:707-716.
30. Law S., Fok M., Chow S., Chu K.M., Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997, 114:210-217.
31. Nygaard K., Hagen S., Hansen H.S., et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992, 16:1104-1109. [discussion 10].
32. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998, 339:1979-1984.
33. Kelsen D.P., Winter K.A., Gunderson L.L., et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25:3719-3725.
34. Group MRCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
35. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Chicago, IL, USA: American Society of Clinical Oncology; 1-5 June 2007 [abstract #4510].
36. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
37. Schuhmacher C, Schlag P, Lordick F, et al. Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial #40954. In: Annual proceedings. Orlando, FL: American Society of Clinical Oncology; 2009 [abstract #4510].
38. Thirion PG, Michiels S, Le Maître A, Tierney J, Group obotMoCiECC. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. Chicago, IL, USA: American Society of Clinical Oncology; 1-5 June 2007 [abstract 4512].
39. Arnott S.J., Duncan W., Gignoux M., et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005, 19:CD001799.
40. Cooper J.S., Guo M.D., Herskovic A., et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. Jama 1999, 281:1623-1627.
41. Apinop C., Puttisak P., Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994, 41:391-393.
42. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337:161-167.
43. Burmeister B.H., Smithers B.M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6:659-668.
44. Le Prise E., Etienne P.L., Meunier B., et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994, 73:1779-1784.
45. Lee J.L., Park S.I., Kim S.B., et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004, 15:947-954.
46. Tepper J., Krasna M.J., Niedzwiecki D., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
47. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305-313.
48. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467.
49. Orringer M.B., Marshall B., Chang A.C., Lee J., Pickens A., Lau C.L. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg 2007, 246:363-372. [discussion 72-4].
50. Stahl M., Walz M.K., Stuschke M., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009, 27:851-856.
51. Fiorica F., Di Bona D., Schepis F., et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004, 53:925-930.
52. Reynolds J.V., Ravi N., Hollywood D., et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg 2006, 132:549-555.
53. D'Angelica M., Gonen M., Brennan M.F., Turnbull A.D., Bains M., Karpeh M.S. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004, 240:808-816.
54. Xiao Z.F., Yang Z.Y., Liang J., et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 2003, 75:331-336.
55. Fok M., Sham J.S., Choy D., Cheng S.W., Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993, 113:138-147.
56. Teniere P., Hay J.M., Fingerhut A., Fagniez P.L. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French university association for surgical research. Surg Gynecol Obstet 1991, 173:123-130.
57. Armanios M., Xu R., Forastiere A.A., Haller D.G., Kugler J.W., Benson A.B. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern cooperative oncology group. J Clin Oncol 2004, 22:4495-4499.
58. Jeung H.C., Rha S.Y., Shin S.J., et al. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemother Pharmacol 2009, 63:919-927.
59. Sun P., Xiang J.B., Chen Z.Y. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009, 96:26-33.
60. Buyse ME, Pignon J. GASTRIC. Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. In: Annual meeting. Chicago, IL: American Society of Clinical Oncology; 2009.
61. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820.
62. Ajani JA, Rodriquez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. In: Annual proceedings. Orlando, FL, USA: American Society of Clinial Oncology; May 29th-June 2nd 2009 [abstract #4511].
63. Liu T.S., Wang Y., Chen S.Y., Sun Y.H. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008, 34:1208-1216.
64. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
65. Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT 0116 (SWOG 9008). In: Annual proceedings. American Society of Clinical Oncology: 2009 [abstract #4515].
66. Kim S., Lim D.H., Lee J., et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005, 63:1279-1285.
67. Coburn N.G., Govindarajan A., Law C.H., et al. Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol 2008, 15:500-507.
68. Valentini V., Cellini F., Minsky B.D., et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol 2009, 92:176-183.
69. Adelstein D.J., Rice T.W., Rybicki L.A., et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol 2009, 6:6.
70. Lee JS, Kang W, Lim D, et al. Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): safety analysis. In: Annual meeting. Chicago, IL: American Society of Clinical Oncology; 2009 [abstract #4537].
71. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
72. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006, 24:4991-4997.
73. Ruhstaller T., Widmer L., Schuller J.C., et al. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol 2009, 20:1522-1528.
74. Ajani J.A., Winter K., Komaki R., et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008, 26:4551-4556.
75. Bains M.S., Stojadinovic A., Minsky B., et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 2002, 124:270-277.
76. Brenner B., Ilson D.H., Minsky B.D., et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004, 22:45-52.
77. Urba S.G., Orringer M.B., Ianettonni M., Hayman J.A., Satoru H. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003, 98:2177-2183.
78. Leichman L, Goldman BH, Benedetti JK, et al. Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): a southwest oncology group (SWOG) phase II trial with molecular correlates (S0356). In: Annual proceedings. Orlando, FL: American Society of Clinical Oncology; 2009 [abstract #4513].
79. Ilson D.H., Bains M., Kelsen D.P., et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003, 21:2926-2932.
80. Ku GY, Bains M, Rizk N, et al. Phase II trial of pre-operative cisplatin/irinotecan and radiotherapy for locally advanced esophageal cancer: PET scan after induction therapy may identify early treatment failure. In: Gastrointestinal Cancer Symposium, Orlando, FL, USA, 25-25 January, 2007 [abstract 9].
81. Kleinberg L, Powell ME, Forastiere A, Keller S, Anne P, Benson AB. E1201: An eastern cooperative oncology group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus. American Society of Clinical Oncology, Chicago, IL, USA, 1-5 June, 2007 [abstract 4533].
82. Kleinberg L, Powell ME, Forastiere AA, Keller S, Anne P, Benson AB. Survival outcome of E1201: an eastern cooperative oncology group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. In: Annual meeting, Chicago, IL: American Society of Clinical Oncology; 2008 [abstract #4532].
83. Henry L.R., Goldberg M., Scott W., et al. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Ann Surg Oncol 2006, 13:214-220.
84. Meluch A.A., Greco F.A., Gray J.R., et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie pearl cancer research network phase II trial. Cancer J 2003, 9:251-260.
85. van de Schoot L., Romme E.A., van der Sangen M.J., et al. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol 2008, 15:88-95.
86. Pasini F, de Manzoni G, Stievano L, Grandinetti A, Maluta S. Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study. In: Annual meeting. Chicago, IL: American Society of Clinical Oncology; 2009 [abstract #4548].
87. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
88. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
89. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
90. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
91. Kelsen DP, Jhawer M, Ilson DH, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial. In: Annual proceedings. Orlando, FL: American Society of Clinical Oncology; 2009 [abstract #4512].
92. Sun W, Powell ME, O'Dwyer P, Ansari RH, Benson AB. A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203). Chicago, IL, USA: American Society of Clinical Oncology; 1-5 June 2008 [abstract 4535].
93. Pinto C., Di Fabio F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18:510-517.
94. Van Cutsem E, Kang K, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). In: Annual proceedings. Orlando, FL, USA: American Society of Clinial Oncology; May 29th-June 2nd 2009 [abstract #LBA 4509].
95. Kulke M.H., Odze R.D., Mueller J.D., Wang H., Redston M., Bertagnolli M.M. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 2004, 127:1579-1586.
96. Langer C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 2004, 58:991-1002.
97. Pegram M.D., Lopez A., Konecny G., Slamon D.J. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000, 27:21-25. [discussion 92-100].
98. Sato S., Kajiyama Y., Sugano M., et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 2005, 61:203-211.
99. Safran H., Suntharalingam M., Dipetrillo T., et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008, 70:391-395.
100. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M. Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: a pilot study from the Hoosier oncology group and the university of Texas Southwestern. In: Annual meeting. Chicago, IL: American Society of Clinical Oncology; 2009.
101. Ruhstaller T, Pless M, Schuller JC, et al. Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase lb-ll trial of the Swiss group for clinical cancer research (SAKK 75/06). In: Annual meeting. Chicago, IL: American Society of Clinical Oncology; 2009 [abstract #4570].
102. Dragovich T., McCoy S., Fenoglio-Preiser C.M., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006, 24:4922-4927.
103. Safran H., Dipetrillo T., Akerman P., et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 67:405-409.
104. Bang Y, Chung H, Sawaki A, et al. HER2-positivity rates in advanced gastric cancer (GC): results from a large international phase III trial. In: Annual proceedings. Chicago, IL: American Society of Clinical Oncology; May-June 2008 [abstract #4526].
105. Ilson DH, Bains M, Rizk N, et al. Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: preliminary safety analysis. In: Gastrointestinal cancer symposium, Orlando, FL, USA, 15-17 January, 2009 [abstract 79].
106. Horgan AM, Darling G, Wong R, et al. Adjuvant sunitinib following chemoradiotherapy and surgery for esophageal cancer: a phase II trial. In: Gastrointestinal cancer symposium, Orlando, FL, USA, 15-17 January, 2009 [abstract 109].
107. Karamouzis M.V., Grandis J.R., Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama 2007, 298:70-82.
108. Warnecke-Eberz U., Vallbohmer D., Alakus H., et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg 2009, 13:1411-1421.
109. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12:1294-1300.
110. Hildebrandt M.A., Yang H., Hung M.C., et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009, 27:857-871.
111. Maher S.G., Gillham C.M., Duggan S.P., et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg 2009, 1:1.
112. Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME. Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): a phase II trial with gene expression profiling (GEP). In: Annual meeting. Chicago, IL: American Society of Clinical Oncology; 2009 [abstract e15543].
113. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8:797-805.
114. Gillham C.M., Lucey J.A., Keogan M., et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006, 95:1174-1179.
115. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American joint committee on cancer (AJCC) 7th ed., 2010.
116. TNM classification of malignant tumours. 7th ed 2009, Wiley, London. L.H. Sobin, M. Gospodarowicz, C. Wittekind (Eds.).
117. Habr-Gama A., Perez R.O., Nadalin W., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004, 240:711-717. [discussion 7-8].
118. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
119. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.